Excited to announce the launch of SPRAVATO®..... Click Here to Learn More →
Seasonal affective disorder (SAD), often called seasonal depression, involves depressive episodes that recur at particular times of year. Winter-pattern symptoms typically begin in fall or early winter and improve as daylight increases in spring. Less commonly, episodes follow a summer pattern.
SAD is not merely disliking cold weather. It may affect concentration, relationships, work, energy, sleep, and daily functioning. Clinicians assess whether the person has major depressive disorder with a seasonal pattern or another condition, including bipolar disorder.
Quick answer: Evidence-based options for winter-pattern SAD include bright light therapy, cognitive behavioral therapy adapted for SAD (CBT-SAD), and appropriate antidepressant medication. Ketamine is not an FDA-approved or established treatment specifically for SAD. Its possible relevance is to an independently diagnosed depressive disorder that has not responded adequately to conventional treatment.

Common symptoms include persistent sadness, reduced interest in activities, fatigue, concentration difficulties, changes in sleep, social withdrawal, and feelings of hopelessness. Winter-pattern SAD can involve oversleeping, increased appetite, and carbohydrate cravings; summer-pattern episodes can involve insomnia, appetite loss, and agitation.
Symptoms lasting two weeks or longer, worsening over time, or disrupting everyday life merit a professional evaluation. A recurring seasonal pattern is useful diagnostic information, but it is not sufficient by itself to determine a diagnosis.
Seasonal depression appears to involve interactions among daylight exposure, circadian rhythms, sleep regulation, and brain systems involved in mood. Reduced daylight may shift the body’s biological clock and influence melatonin timing. Researchers also study seasonal changes in serotonin-related signaling.
Vitamin D levels may fall when sunlight exposure decreases, but vitamin D supplements have not consistently been shown to treat SAD. Seasonal depression cannot be reduced to one chemical deficiency or one environmental cause.
Ketamine affects glutamate-related signaling, a pathway different from the primary targets of many conventional antidepressants. In research involving treatment-resistant major depression, some patients experience antidepressant improvement within hours or approximately one day. Those findings do not establish that ketamine treats SAD specifically.
NMDA receptor activity: Ketamine blocks N-methyl-D-aspartate (NMDA) receptors, changing glutamate signaling in the brain.
AMPA signaling: Downstream effects involving AMPA receptors are believed to contribute to ketamine’s antidepressant action.
Neuroplasticity: Preclinical studies link ketamine to pathways involving brain-derived neurotrophic factor (BDNF), mTOR signaling, and synaptic adaptation. The full mechanism in humans remains under study.
Rapid antidepressant response: Some people with treatment-resistant depression improve relatively quickly, while others do not respond. Benefits after a single treatment may be temporary.
Importantly, ketamine does not replace daylight exposure, correct a circadian rhythm disorder, or directly reverse a proven biological cause of SAD. Its consideration should follow a careful diagnosis and review of previous treatments.
There is not sufficient SAD-specific clinical evidence to describe ketamine as an established seasonal depression treatment. Intravenous ketamine is FDA-approved as an anesthetic, and its psychiatric use is off-label. SPRAVATO® (esketamine) has FDA-approved indications for certain depressive conditions in adults, but not specifically for SAD.
A patient with recurring winter depression might also meet criteria for treatment-resistant major depressive disorder. In that situation, a qualified clinician may assess whether a ketamine-based treatment is appropriate for the underlying diagnosis. Response, risks, monitoring needs, and ongoing care must be discussed individually.
Bright light therapy: For winter-pattern SAD, clinicians often recommend a purpose-built light box, commonly 10,000 lux for roughly 30–45 minutes in the morning. People with bipolar disorder, certain eye conditions, or photosensitizing medicines should seek guidance first.
CBT-SAD: This specialized psychotherapy addresses seasonal patterns of thinking and behavior and can help patients build coping strategies for future winters.
Antidepressants: Medication may be appropriate for moderate or severe depression. Bupropion XL has an FDA-approved indication for prevention of seasonal major depressive episodes in selected adults.
Supportive routines: Consistent sleep, regular activity, outdoor daylight exposure, and social contact can complement treatment but are not substitutes for clinical care when depression is significant.
Seasonal depression describes the timing of depressive episodes. Treatment-resistant depression describes an inadequate response to appropriately delivered treatments. A person can have both, but one diagnosis does not automatically establish the other.
An evaluation may also identify bipolar disorder, sleep disorders, thyroid conditions, medication effects, or other contributors to symptoms. These distinctions matter when choosing light therapy, medication, or ketamine-based care.
IV ketamine is administered by infusion under medical supervision and is used off-label for depression. SPRAVATO® is an esketamine nasal spray administered in a certified healthcare setting under REMS requirements, including at least two hours of post-dose monitoring.
Neither is FDA-approved specifically for SAD. Insurance coverage differs by treatment, diagnosis, plan, and medical-necessity criteria; eligibility should be checked individually.
Tennessee Ketamine & Wellness Center serves patients seeking an individualized evaluation for depression in Franklin and the surrounding Middle Tennessee region. If conventional depression treatments have not provided adequate relief, a clinical consultation can help clarify whether ketamine-based treatment is a reasonable option for the underlying depressive disorder.
Learn more about treatment services: https://tnketaminewellness.com/ketamine-therapies/
To explore eligibility and next steps, contact Tennessee Ketamine & Wellness Center through https://tnketaminewellness.com/.
Seek professional care when depressive symptoms persist, recur seasonally, interfere with work or relationships, or fail to improve with previous treatment. Do not wait for the season to change if symptoms are severe.
In a crisis: If you or someone else is at immediate risk, call 911. In the U.S., call or text 988 for the Suicide & Crisis Lifeline: https://988lifeline.org/
Winter-pattern episodes often start in fall or early winter and ease during spring, though timing varies.
No. SAD involves clinically significant depression and can impair daily functioning.
Yes. Seasonal depression can occur in Tennessee and other regions where daylight changes throughout the year.
Anxiety and irritability can accompany depression; a clinician can assess co-occurring conditions.
No. Correcting deficiency can be important, but evidence for vitamin D as a SAD treatment is inconsistent.
Light therapy is an established option for winter-pattern SAD, with individual safety considerations.
Some patients with treatment-resistant depression respond within hours or a day, but this is not a demonstrated SAD-specific outcome.
No. IV ketamine is used off-label for psychiatric conditions, and SPRAVATO® is not specifically approved for SAD.
Possibly, if a separate qualifying depressive disorder is established after clinical evaluation; seasonal symptoms alone do not establish eligibility.
For some patients, a clinician-guided preventive plan using CBT-SAD, light therapy, or medication can reduce recurrence.
Medical disclaimer: This article is educational and does not replace individualized medical advice. Clinical appropriateness of ketamine-based treatment must be determined by a qualified healthcare professional.